Kaplan-Meier estimates of DFS and OS. Data from the ITT analysis are shown for DFS (A) and OS (B) of all patients treated in the autologous randomization arms of the trial. Data are from the time of randomization at the start of consolidation. The investigational arm contained the additional treatment with gemtuzumab ozogamicin. CNSR indicates censured.